← brief for 2026-10-16 · Slowing decline

Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence

Article No results yet Peer reviewed

Key takeaways

This review looks at new immune drugs for kidney disease. It explains why these drugs might work better than older ones. It is a summary of existing science, so it reports no new trial results.

Who did this work

Mehmet Kanbay (Koç University) · Sidar Çöpür (Koç University) · Ibrahim Gulmaliyev (Koç University) · Caner Süsal (Koç University) · Caner Süsal (Koç University) · Adrian Covic (Grigore T. Popa University of Medicine and Pharmacy) · Mahmut Altındal (Koç University)

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-10-15
https://doi.org/10.1093/ndt/gfag238